CSIMarket
 
Lianbio  (LIAN)
Other Ticker:  
 
 
Price: $0.3478 $-4.64 -93.030%
Day's High: $0.3888 Week Perf: -92.93 %
Day's Low: $ 0.27 30 Day Perf: -92.69 %
Volume (M): 23,229 52 Wk High: $ 4.99
Volume (M$): $ 8,079 52 Wk Avg: $2.90
Open: $0.28 52 Wk Low: $0.27



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 107
 Employees 600
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Lianbio
LianBio is a biopharmaceutical company headquartered in Shanghai, China. The company was established in 2019 by industry veterans with decades of experience in drug development, commercialization, and investment from leading biopharmaceutical companies such as Pfizer, Amgen, and Johnson & Johnson.

LianBio aims to become a market leader in the development and commercialization of innovative therapies for unmet medical needs in China and other global markets. The company's strategy is to leverage its network, knowledge, and expertise to identify promising drug candidates from academia and industry, and then to provide funding, development resources, and global commercialization capabilities to bring these therapies to market.

LianBio has a broad pipeline of more than ten programs in various stages of development, ranging from early-stage research to late-stage clinical trials. The company focuses on a range of therapeutic areas, including oncology, immunology, metabolic diseases, and neurology. LianBio's programs include both small molecules and biologics, with a strong emphasis on precision medicine and personalized therapies.

LianBio has established partnerships with leading academic and research institutions, pharmaceutical companies, and investors across the globe, including in the US, Europe, and Asia. The company has raised significant capital from leading investors, including Hillhouse Capital, Boyu Capital, Sequoia Capital China, and Temasek.

LianBio has a strong management team with extensive experience in drug development and commercialization, including key executives who have held senior leadership positions in some of the world's leading biopharmaceutical companies. The company's management team is supported by more than 200 employees who are dedicated to advancing the company's mission of improving patients' lives through innovative therapies.

Overall, LianBio is a rapidly growing biopharmaceutical company with a broad pipeline of innovative therapies and a strong focus on precision medicine and personalized therapies. With a strong management team, partnerships with leading institutions and investors, and a commitment to advancing the science of drug development, LianBio is poised for long-term success in the rapidly evolving biopharmaceutical industry.


   Company Address: 103 Carnegie Center Drive Princeton 8540 NJ
   Company Phone Number: 486-2308   Stock Exchange / Ticker: NASDAQ LIAN
   LIAN is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

The Journey of LianBio: Voluntarily Delisting from Nasdaq and Partnering with Jillian Switzerland for Perfume Innovation

Published Wed, Feb 28 2024 12:01 PM UTC

In a recent announcement, LianBio, a prominent biotechnology company focused on delivering groundbreaking medicines to patients in China and other Asian markets, revealed its decision to voluntarily delist its American Depositary Shares (ADSs) from the Nasdaq Global Market. Concurrently, luxury perfume brand Jillian Switzerland launched an exciting new collection of signatur...

Management Announcement

Komprise Doubles Subscriptions Again in 2023 As Enterprises Seek to Leverage Unstructured Data for AI

Published Wed, Feb 14 2024 3:00 PM UTC


In a recent press release, data management platform Komprise announced that it has experienced a significant boost in business, with a doubling of subscriptions in 2023. This growth can be attributed to both the increase in new customers as well as the expanded adoption of their unstructured data management platform. The surge in demand for their services highlights the...

Shares

LianBio Initiates Comprehensive Wind-Down Strategy, Unlocking Value and Focusing on Future Opportunities

Published Tue, Feb 13 2024 12:00 PM UTC



In an official press release yesterday, LianBio, a leading biotechnology company, announced its decision to commence the wind-down of its operations. The strategic move involves the sale of remaining assets, reduction in force, delisting from Nasdaq, and issuance of a special cash dividend. This article aims to delve into the significance of LianBio's decision, its...

Product Service News

LianBio Advances Oncology Treatment: Assigns Rights to Janssen for NBTXR3 Development in Asia

Published Tue, Dec 26 2023 7:00 AM UTC

In a significant development for the biotechnology sector, LianBio, a leading player focused on accelerating the differentiation and development of innovative medicines in China and other major Asian markets, has announced an agreement with Janssen Pharmaceutica NV. According to the ground-breaking agreement that hails from Shanghai, China and Princeton, New Jersey, LianBio ...

Management Announcement

LianBio's CEO Yizhe Wang Departs Amidst Strong Growth, Paving the Way for a New Era in Biotechnology

Published Tue, Dec 19 2023 9:05 PM UTC

LianBio Announces Resignation of CEO Yizhe Wang, Ph.D., Amidst Steady Growth in the Biotechnology Industry
SHANGHAI, China, and PRINCETON, N.J., Dec. 19, 2023 - LianBio (Nasdaq: LIAN), a leading biotechnology company committed to introducing groundbreaking treatments to patients in China and other significant Asian markets, has revealed that its Chief Executive Officer,...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com